Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikace versus tobramycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection
2011-000441-20Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amikacin liposome inhalation suspension in Pseudomonas aeruginosa pulmonary infection and cystic fibrosis (CF) (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Relative change in FEV1 from baseline to end of study. Started Apr 2011; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Pseudomonas aeruginosa pulmonary infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on 2011-000441-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000441-20.